Related Experiment Video
Updated: Jul 12, 2025
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.7K
Use of second-generation antidiabetic medication among a nationally representative sample
Bang Truong, Yuexin Li, Jingyi Zheng
1Department of Health Outcomes Research and Policy, Auburn University Harrison College of Pharmacy, 4306d Walker Building, Auburn, AL 36849.
The American Journal of Managed Care
|October 23, 2023
Summary
Second-generation antidiabetic drugs were used by 14% of type 2 diabetes patients in the US. Higher income, increased medication use, and elevated hemoglobin A1c levels were linked to their prescription.
Area of Science:
- Endocrinology
- Pharmacology
- Public Health
Background:
- Second-generation antidiabetic medications offer benefits for type 2 diabetes (T2D) management.
- Real-world utilization patterns of these medications remain incompletely understood.
- Assessing patient factors influencing the adoption of these drugs is crucial for optimizing T2D care.
Purpose of the Study:
- To investigate patient characteristics associated with the use of second-generation antidiabetic medications.
- To analyze real-world data on the uptake of newer antidiabetic therapies in a representative US population with T2D.
Main Methods:
- Retrospective, cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data from 2005-2018.
- Inclusion criteria: adults (≥18 years) with diagnosed T2D using antidiabetic medications within 30 days.
- Weighted multivariable logistic regression models assessed associations between patient factors and second-generation antidiabetic drug use.
Main Results:
- Approximately 13.67% of 4493 T2D patients reported using at least one second-generation antidiabetic drug.
- Higher income (≥400% federal poverty level), increased medication burden, and higher hemoglobin A1c levels were significantly associated with the use of these medications.
- Adjusted odds ratios indicated a greater likelihood of use for patients with these characteristics.
Conclusions:
- The utilization of second-generation antidiabetic medications among US patients with T2D was approximately 14%.
- Factors such as higher socioeconomic status and greater disease severity appear to influence the prescription of these newer agents.
- Policy interventions, such as optimizing prescription benefit designs to reduce out-of-pocket costs, could enhance patient access and improve clinical outcomes.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
01:06Oral Hypoglycemic Agents: Glinides
160
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
160
01:17Oral Hypoglycemic Agents: Sulfonylureas
215
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
215
01:22Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
01:24Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334
01:23Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192